Antihypertensive medication use and ovarian cancer survival

Huang, Tianyi; Townsend, Mary K.; Dood, Robert; Sood, Anil K.; Tworoger, Shelley S.

doi:10.1016/j.ygyno.2021.09.009

Cited by 5 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multivariate analysis showed that ovarian cancer patients, who took calcium channel blockers before surgery, had an increased risk of death compared with those who did not take a such drug (HR: 1.49, 95% CI 1.13–1.96). However, no association was found between taking thiazide diuretics, beta-blockers, or angiotensin-converting enzyme inhibitors (ACEI) and cancer risk [ 35 ]. A meta-analysis found similar results from 33 studies [ 36 ].…”

Section: Metabolic Syndrome Its Components and Thyroid Cancer Riskmentioning

confidence: 99%

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism

Song

Liu

et al. 2023

Discov Onc

View full text Add to dashboard Cite

The increasing incidence of thyroid cancer (TC) cannot be fully explained by overdiagnosis. Metabolic syndrome (Met S) is highly prevalent due to the modern lifestyle, which can lead to the development of tumors. This review expounds on the relationship between Met S and TC risk, prognosis and its possible biological mechanism. Met S and its components were associated with an increased risk and aggressiveness of TC, and there were gender differences in most studies. Abnormal metabolism places the body in a state of chronic inflammation for a long time, and thyroid-stimulating hormones may initiate tumorigenesis. Insulin resistance has a central role assisted by adipokines, angiotensin II, and estrogen. Together, these factors contribute to the progression of TC. Therefore, direct predictors of metabolic disorders (e.g., central obesity, insulin resistance and apolipoprotein levels) are expected to become new markers for diagnosis and prognosis. cAMP, insulin-like growth factor axis, angiotensin II, and AMPK-related signaling pathways could provide new targets for TC treatment.

show abstract

Section: Metabolic Syndrome Its Components and Thyroid Cancer Riskmentioning

confidence: 99%

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism

Song

Liu

et al. 2023

Discov Onc

View full text Add to dashboard Cite

show abstract

“…However, part retrospective analyses of BBs show (Table 2 ) that there are conflicting claims about whether BBs alone can improve OS and progression-free survival (PFS) in patients [ 152 – 161 ]. The potential benefits of BBs may be offset by anxiety and depression [ 159 ]. Notably, β-ARs have different roles across tumor types and there is selective heterogeneity in the BBs [ 160 ].…”

Section: Treatment For Cancer Patients With Chronic Stressmentioning

confidence: 99%

Chronic stress in solid tumor development: from mechanisms to interventions

et al. 2023

View full text Add to dashboard Cite

Chronic stress results in disturbances of body hormones through the neuroendocrine system. Cancer patients often experience recurrent anxiety and restlessness during disease progression and treatment, which aggravates disease progression and hinders treatment effects. Recent studies have shown that chronic stress-regulated neuroendocrine systems secret hormones to activate many signaling pathways related to tumor development in tumor cells. The activated neuroendocrine system acts not only on tumor cells but also modulates the survival and metabolic changes of surrounding non-cancerous cells. Current clinical evidences also suggest that chronic stress affects the outcome of cancer treatment. However, in clinic, there is lack of effective treatment for chronic stress in cancer patients. In this review, we discuss the main mechanisms by which chronic stress regulates the tumor microenvironment, including functional regulation of tumor cells by stress hormones (stem cell-like properties, metastasis, angiogenesis, DNA damage accumulation, and apoptotic resistance), metabolic reprogramming and immune escape, and peritumor neuromodulation. Based on the current clinical treatment framework for cancer and chronic stress, we also summarize pharmacological and non-pharmacological therapeutic approaches to provide some directions for cancer therapy.

show abstract

“…Hypertension is a common comorbidity in patients with cancer. A number of large cohort studies on the association between the antihypertensive medication use and ovarian cancer death risk showed a significant beneficial effect of post-diagnostic angiotensin-converting enzyme inhibitors (ACE inhibitors) use on cancer-specific survival compared to not users [ 6 , 7 ]. Moreover, in a study of women 66 + years of age with ovarian cancer, lower cancer-specific mortality was shown in patients who received ACE inhibitors or diuretics during the year following a cancer diagnosis [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, in a study of women 66 + years of age with ovarian cancer, lower cancer-specific mortality was shown in patients who received ACE inhibitors or diuretics during the year following a cancer diagnosis [ 8 ]. A protective effect of angiotensin-receptor blockers (ARBs) has been observed among epithelial ovarian cancer patients by Cho et al [ 9 ]; however, no clear associations between post-diagnostic ARBs or beta-blockers (BBs) use and ovarian cancer mortality were found in cohort studies by Santala et al or Huang et al [ 6 , 7 ]. The results of several recent studies suggested survival benefits for BBs users, particularly for nonselective BBs users [ 8 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…In recent meta-analyses it was concluded, that there is insufficient evidence regarding the association between ACE inhibitors or BBs and ovarian cancer survival [ 12 , 16 ]. Consumption of other antihypertensive drug groups (calcium channel blockers (CCBs) or diuretics) was not associated with a decreased ovarian cancer death risk, except the elevated risk observed with furosemide use [ 6 , 7 , 9 ]. We found no studies aiming to examine the role of centrally and peripherally acting antiadrenergic agents (SNS-AH) in ovarian cancer survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study

Everatt,

Kuzmickienė,

Brasiūnienė

et al. 2024

BMC Women's Health

View full text Add to dashboard Cite

Background Despite declining mortality in most countries and in Lithuania, ovarian cancer burden has remained high. Studies have indicated that antihypertensive medications use may help to improve ovarian cancer survival, however findings remain controversial. The aim of the study was to analyse the association between post-diagnosis antihypertensive medications intake and cancer-specific survival in ovarian cancer patients. Methods This retrospective cohort study included 588 ovarian cancer cases diagnosed between 2013 and 2015. Hazard ratios (HR) and corresponding 95% confidence intervals (95%CI) were estimated using multivariable Cox proportional hazards models to assess associations between antihypertensive medications and ovarian cancer-specific mortality. Results In total, 279 (47%) patients died during the follow-up; 242 (87%) of them died due to ovarian cancer. The risk of ovarian cancer death was reduced in angiotensin-converting enzyme inhibitors (ACE inhibitors) users vs. non-users (HR 0.55, 95% CI: 0.36–0.83). Subgroup analysis showed better ovarian cancer survival in higher dose ACE inhibitors users (HR 0.46, 95% CI: 0.28–0.77, p for trend 0.002); the effect was also stronger in age 51–65 years, stage I–III, surgery or chemotherapy treatment, pre-diagnosis ACE inhibitor users’ and pre-diagnosis hypertension subgroups. The risk of cancer-specific death was slightly lower among calcium-channel blocker and angiotensin-receptor blocker users and higher among beta-blocker users as compared to non-users, however chance and confounding could not be ruled out. We found no association between the use of centrally and peripherally acting antiadrenergic agents and diuretics and risk of ovarian cancer-specific mortality. Conclusions Our findings imply that post-diagnosis use of ACE inhibitors may be associated with reduced ovarian cancer-specific mortality; however, further research is needed for the comprehensive assessment.

show abstract

Antihypertensive medication use and ovarian cancer survival

Cited by 5 publications

References 43 publications

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism

Chronic stress in solid tumor development: from mechanisms to interventions

Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study

Contact Info

Product

Resources

About